News & Events

BD Medical – Ophthalmic Systems, a unit of BD (Becton, Dickinson and Company), announced today the launch of its expanded line of BD Visitec™ stainless steel single-use instruments.

“BD is pleased to expand our offering of single-use microsurgical instruments to meet the challenges of infection transmission prevention and help facilities around the world comply with strict safety requirements,” said Doug Lawrence, Vice President and General Manager, BD Medical - Ophthalmic Systems. “This launch reflects BD’s continued commitment to developing safety-engineered, single-use medical devices designed to protect patients and healthcare workers against the threat of cross- contamination and bloodborne diseases.”

With the addition of 30 new instruments and customized trays, healthcare facilities have the potential to increase efficiency by eliminating the need for costly and time-consuming re-sterilization of each product.

“Advances in ophthalmic surgical techniques make it possible for surgeons to perform more procedures in less time, thereby increasing the number of patients who can benefit from improved vision,” said Randall Olson, M.D., CEO of the John A. Moran Eye Center and Chairman of the Department of Ophthalmology and Visual Sciences at the University of Utah.“However, this increase in ophthalmic procedures is leading to growing concern over instrument sterility. In this environment, single-use instruments can provide ophthalmic surgeons with immediate access to sterile instruments.”

BD is a pioneer in developing single-use solutions to meet the changing needs of ophthalmic surgery. BD Visitec stainless steel instruments help to further patient and healthcare worker safety with high-quality, innovative, safety-engineered products designed to eliminate the risk of transmitting infectious agents. For more information, please visit: www.bd.com/ophthalmology.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.